EGFR and lung adenocarcinoma: Epidermal growth factor receptor (EGFR)-activating mutations [exon 19 deletion mutation and exon 21 L858R substitution mutation (L858R)] are the most and second most frequently identified driver alterations of lung adenocarcinoma in East Asian and Western countries, respectively1–3.